insights_auto
Por que GNLX subiu 2,40%?
Saiba maischevron_right
GNLX:NASDAQ
Genelux Corp
US$ 2,56
arrow_upward
+2,40%(+0,060) 1D
9 de out., 16:00:01 GMT-4 · USD
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para GNLX…
Abrir
US$ 2,48
Alta
US$ 2,57
Baixa
US$ 2,47
Valor de mercado
115,83 mi
Volume médio
275,44 mil
Volume
154,65 mil
Alto — 52 sem
US$ 8,54
Baixo — 52 sem
US$ 2,29
LPA
-US$ 0,87
Beta
0,59
Ações em circulação
45,24 mi
Nº de funcionários
26
Abrir
US$ 2,48
Alta
US$ 2,57
Baixa
US$ 2,47
Valor de mercado
115,83 mi
Volume médio
275,44 mil
Volume
154,65 mil
Alto — 52 sem
US$ 8,54
Baixo — 52 sem
US$ 2,29
LPA
-US$ 0,87
Beta
0,59
Ações em circulação
45,24 mi
Nº de funcionários
26
Notícias
De fontes da web e parceiros de notícias
https://www.dars.gov.et/
·
há 1 semana
Genelux Corporation (GNLX) Slips 0.40% to $2.52 as Shares Hold Above Near-Term Support - Momentum Surge Alerts
Perfil
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Sobre Genelux Corp
CEO-
Funcionários26
Data de fundação2001
SedeWestlake Village, Califórnia, Estados Unidos
Setor-
Sitegenelux.com